Therapeutic failure and relapse in peptic ulcer

Area of Science:

• Gastroenterology
• Pharmacology

Background:

• Peptic ulcer (PU) treatment focuses on healing the ulcer, not the underlying disease.
• Therapeutic failures in peptic ulcer treatment are common, with unclear causes and no reliable method for predicting them.
• Patients with treatment-resistant ulcers do not exhibit distinct gastric acid secretion or drug absorption patterns.

Purpose of the Study:

• To explore the reasons behind therapeutic failures in peptic ulcer treatment.
• To evaluate current and potential therapeutic strategies for improving peptic ulcer cure rates.
• To investigate the role of gastric mucosal defense mechanisms in treatment resistance.

Main Methods:

• Analysis of existing observations on peptic ulcer treatment outcomes.
• Comparison of different therapeutic approaches, including H2-antagonists and cytoprotective drugs.
• Evaluation of the impact of drug potency and treatment duration on healing rates.

Main Results:

• Increased doses of H2-antagonists do not improve antisecretory effects or cure rates.
• Prolonging H2-antagonist therapy can cure some patients, but not all.
• Prolonged cytoprotective drug treatment shows promise, suggesting impaired mucosal defense mechanisms.
• Potent antisecretory drugs like omeprazole achieve near-universal healing.
• A combination of antisecretory and cytoprotective effects may reduce treatment failures.

Conclusions:

• Altered gastric mucosal defense mechanisms may be a primary factor in treatment-resistant peptic ulcers.
• Bivalent drugs combining antisecretory and cytoprotective actions could potentially decrease treatment failures.
• The ultimate goal remains to treat the underlying cause of peptic ulcers, not just the symptoms.